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Abstract 
Reaction of salicylhydroxamic acid (Sha) and 2-aminophenyl hydroxamic acid (2-NH2-pha) 
with BiCl3 affords the corresponding novel polymeric bismuth chlorido hydroxamato complexes; 
[BiCl2(-Sha-1H)]∞ and [BiCl3(--Pha-1H)]∞ respectively. The X-ray crystal structure of the THF-
solvated polymeric bismuth chlorido salicylhydroxamato complex, [BiCl2(-Sha-1H)(THF)]∞ was 
solved, confirming the polymeric structure of this class of compounds and the (O,μ-O’)-bidentate 
bridging coordination mode of the hydroxamato ligand. The antibacterial activity of the THF-free 
polymeric bismuth chlorido salicylhydroxamato complex, [BiCl2(-Sha-1H)]∞, was investigated against 
a broad panel of bacteria, further highlighting the antibacterial properties of Bi-based compounds 
against Gram-positive and Gram-negative pathogenic and environmental strains of bacteria. 
 
Keywords:  Bismuth; hydroxamic acid; polymer, antibacterial. 
1. Introduction 
 Hydroxamic acids, of general formula RCONHOH, represent a very important 
family of bioligands, Figure 1(a).[1]  One of the first roles attributed to hydroxamic 
acids is their use as siderophores, a class of low molecular weight iron (Fe)-
sequestering agents involved in microbial iron transport. Desferal for example, a 
natural trihydroxamic acid siderophore, which forms an Fe(III) trishydroxamato 
complex, Ferrioxamine-B, with log  ~ 30, is clinically used to treat Fe overload, 
Figure 1(b).[1]  
 Hydroxamic acids are therefore effective metal chelators and as ligands, 
classically coordinate metal centres in an (O,O’) bidentate chelating fashion, 
coordinating through the carbonyl oxygen atom and the deprotonated hydroxyl 
group, Figure 1(c), to form very stable five-membered hydroxamato chelates.[2, 3] 
Other binding modes are possible, including monodentate binding through the 
deprotonated nitrogen or oxygen atoms and bidentate binding of two metal ions 
has also been observed in an (O,μ-O’) chelating mode, Figure 1(d).[2-4] 
Significantly the complexation behaviour of hydroxamic acids can be enriched by 
the incorporation of secondary coordinating groups, such as a hydroxy or an amino 
group, at neighbouring sites in the molecule.[2, 3] In turn hydroxamic acids have 
been employed to develop a diverse range of interesting complexes including 
metallacrowns, coordination polymers and cluster complexes.[2, 3]  
 
 Figure 1. (a) General structure for hydroxamic acids, (b) structure of 
Ferrioxamine-B, (c) representation of hydroxamato (O,O’) chelating mode and 
(d) representation of hydroxamato (O,-O’) chelating mode. 
 
More recently the versatile coordination chemistry of hydroxamic acids has 
facilitated the development of important inhibitors of metalloenzymes such as GSK-
1322322, a peptide deformylase inhibitor and antibacterial agent, Figure 2 (a),[5] and 
suberoylanilide hydroxamic acid, SAHA, a potent histone deacetylase (HDAC) 
inhibitor and anti-cancer agent, Figure 2 (b).[6-8]  
 We are currently interested in the reactivity of hydroxamic acids with 
bismuth, of which there has been few reports in the literature.[9-11] We recently, 
for example, reported a novel class of Bi(III) hydroxamato nitrato complexes and 
the urease inhibitory activity and antibacterial activity against H. pylori of the Bi 
benzohydroxmato complex, [Bi2(Bha-1H)2(μ-Bha-1H)2(η
2
-NO3)2], Figure 2 (c).[11] 
 Figure 2. Structures of (a) SAHA, (b) GSK1322322 and (c) [Bi2(Bha-
1H)2(μ-Bha-1H)2(η
2
-NO3)2]. 
  Prior to the discovery of antibiotics numerous different Bi preparations were 
used as treatments for bacterial infections associated with wounds, cholera and 
gastroenteritis.[12] The development of antibiotics in the 1940’s drastically reduced 
the use of Bi-based antibacterial medications until the discovery of the gastric 
pathogen H. pylori in the 1980s.[12]
 
Currently
 
Bi-containing quadruple therapies for 
H. pylori represent a successful strategy for overcoming multidrug bacterial 
resistance.[13, 14] 
Metallomic and metalloproteomic approaches have been employed to 
investigate the potential antibacterial mechanism of action of Bi against H. pylori for 
example and strong evidence suggests that Bi interference with metal 
homeostasis and oxidation reduction processes may be important.[15-19] 
Considering Bi strong association with effective treatment for H. pylori it is 
very surprising that there are so few reports in the literature on the investigation of the 
activity of Bi compounds against bacteria in addition to H. pylori.[20] Furthermore 
given infection involving multidrug bacterial resistance represents an emergent global 
disease and a major global health challenge there is an urgent need to develop new 
classes of effective antibacterial agents.[21] 
We hypothesised that reaction of Bismuth chloride, BiCl3, with 
salicylhydroxamic acid (Sha) and 2-aminophenyl hydroxamic acid (2-apha) would 
generate interesting Bi(III) hydroxamato complexes, particularly as the availability of 
the hydroxyl group, amino groups or pyridine nitrogen at the 2-position respectively, 
might act as anchors and encourage (OOH,O) or (NNH2,O)  hydroxamato coordination 
respectively to Bi(III).  
 
 
Figure 3. Structures of (a) Salicylhydroxamic acid and (b) 2-
aminophenylhydroxamic acid. 
 
Herein, we report the synthesis and characterisation of novel polymeric Bi(III) 
chlorido complexes of salicylhydroxamic acid and 2-aminophenylhydroxamic acid. 
The X-ray crystal structure of the THF-solvated polymeric complex, [BiCl2(-Sha-
1H)(THF)]∞ was determined and the antibacterial activity of the THF-free complex, 
[BiCl2(-Sha-1H)]∞, against a broad panel of bacteria investigated. 
 
2. Experimental 
2.1. Materials  
Salicylhydroxamic acid, BiCl3, Ampicillin and deuterated solvents were 
purchased from Sigma Aldrich and used without further purification. 2-NH2-phawas 
synthesised as previously reported.[22] 
 
2.2. Synthetic methods 
IR spectra were recorded using a Bruker VERTEX 70/70v FT-IR spectrometer 
using KBr discs (4000-400 cm
-1
). The spectra were analysed using OPUS software. 
1
H NMR spectra were recorded on a Bruker Avance 400 NMR spectrometer. The 
spectra were analysed using MestReNova software. The residual undeuterated d
4
-
Methanol signal at 3.31 ppm was used as an internal reference. Mass spectrometry 
experiments were performed on an Advion Expression Compact Mass Spectrometer 
where 10 μL of the samples were injected in 300 μL of methanol:water:formic acid 
(90:9:1 v/v). The mass spectrometry data were acquired both in positive and negative 
ion modes and the spectra analysed using the Advion Mass Express software 
programme. 
Elemental analysis (C, H and N) was performed at the Microanalytical 
Laboratory, School of Chemistry and Chemical Biology, University College Dublin, 
Ireland. 
 
2.3. Syntheses  
2.3.1. Synthesis of [BiCl2(-Sha-1H)]∞ 
 Anhydrous THF (25 mL) was added to BiCl3 (470 mg, 1.49 mmol) and Sha 
(265 mg, 1.7 mmol) in a dry round bottomed flask under Argon. The reaction was 
stirred at room temperature for three days. The reaction mixture was concentrated in 
vacuo to c. 5 mL.   H2O (5 mL) was added resulting in precipitation of a light yellow 
solid, which was filtered and dried, 370 mg (88 %). Elemental analysis: 
(C7H6BiCl2NO3) Calc. (Found): C  19.46 (19.4), H 1.4 (1.14), N 3.24 (2.84), Cl 16.41 
(13.58) %; 1H NMR (400 MHz, CD3OD, 25 °C, d = doublet, t = triplet, s = singlet, br 
= broad, m = multiplet): 7.91 (d, J = 8.1 Hz, 1H, Aromatic H), 7.40 (t, J = 7.0 Hz, 
1H, Aromatic H),  6.93 (m, 2H, aromatic H); IR (KBr disc, br = broad, s = strong, vs 
= very strong) max/cm
-1
: 3230 (s, O-H), 1604 (s, C=O); MS (ESI+) m/z: 396.1 
BiCl(Sha-1H), 512.9 Bi(Sha-1H)2.  
Single crystals of [BiCl2(-Sha-1H)(THF)]∞ were formed upon standing of the 
filtrate. Elemental analysis; (C15H22BiCl2NO4) Calc. (Found): C 31.27 (30.85), H 3.85 
(3.63), N 2.43 (2.20), Cl 12.30 (10.26) %. 
 
2.3.2. [BiCl3(--Pha-1H)]∞ 
 Anhydrous THF (35 mL) was added to BiCl3 (490 mg, 1.55 mmol) and 2-
NH2-Pha (269 mg, 1.76 mmol) in a dry round bottomed flask under Argon. The 
reaction was stirred at room temperature for three days. A yellow precipitate was 
filtered and dried, 360 mg (49 %). Elemental analysis; (C7H7BiCl2N2O2.0.1C4H8O) 
Calc. (Found): C  18.72 (18.84), H 1.87 (1.72), N 5.90 (5.92), Cl 22.40 (22.46) %; 
1
H 
NMR (400 MHz, CD3OD),  δH: 7.70 (d, 
3
J = 8 Hz, 1H, Aromatic H),  7.60 (t, 
3
J = 8 
Hz, 1H, Aromatic H),  7.38 (m, 2H, Aromatic H); IR (KBr disc) max/cm
-1
: 1614 (s, 
C=O); MS (ESI+) m/z:  430.9 BiCl2(2-NH3-pha-1H) and 619 BiCl3(2-NH3-pha-1H)2. 
 
2.4. X-Ray data collection and structure determination for [BiCl2(-Sha-1H)(THF)]∞.
 Crystal data for [BiCl2(THF)(-Sha-1H)]∞ were collected with Mo-Kα radiation 
(0.71073 Å) using an Rigaku Oxford Diffraction (former Agilent Technologies, 
former Oxford Diffraction) SuperNova A diffractometer fitted with an Atlas detector. 
A five times redundant dataset was collected, assuming that the Friedel pairs are not 
equivalent. An analytical absorption correction based on the shape of the crystal was 
performed.[24] The structures were solved by direct methods using SHELXS-97[25] 
and refined by full matrix least-squares on F
2
 for all data using SHELXL-97.[25] 
Hydrogen atoms were added at calculated positions and refined using a riding model. 
Their isotropic temperature factors were fixed to 1.2 times (1.5 times for methyl 
groups) the equivalent isotropic displacement parameters of the carbon atom the H-
atom is attached to. Anisotropic thermal displacement parameters were used for all 
non-hydrogen atoms. 
 
Table 1.  
Crystallographic data collection and structure refinement for [BiCl2(-Sha-
1H)(THF)].THF∞ 
Empirical formula  C15 H22 N O5 Cl2 Bi 
Molecular formula C11 H14 N O4 Cl2 Bi x C4 H8 O 
Formula weight  576.22 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  Pna21 (#33) 
Unit cell dimensions a = 16.6571(1) Å = 90°. 
 b = 33.0779(3) Å = 90°. 
 c = 20.4220(2) Å  = 90°. 
Volume 11252.15(16) Å3 
Z 24 
Density (calculated) 2.041 Mg/m3 
Absorption coefficient 9.710 mm–1 
F(000) 6624 
Crystal size 0.3408 x 0.1964 x 0.1525 mm3 
Theta range for data collection 2.93 to 29.69°. 
Index ranges –22<=h<=20, –43<=k<=45, –
27<=l<=27 
Reflections collected 122294 
Independent reflections 27266 [R(int) = 0.0361] 
Completeness to theta = 28.00° 99.0 %  
Absorption correction Analytical 
Max. and min. transmission 0.319 and 0.102 
Refinement method Full–matrix least–squares on F2 
Data / restraints / parameters 27266 / 23 / 1304 
a)
 
Goodness–of–fit on F2 1.059 
Final R indices [I>2sigma(I)] R1 = 0.0342, wR2 = 0.0842 
R indices (all data) R1 = 0.0355, wR2 = 0.0859 
Absolute structure parameter 0.325(3) 
b)
 
Largest diff. peak and hole 1.999 and –1.650 e.Å–3 
  
a)
 ISOR and DELU restraints were applied to O(2) and O(5) in order to stop them from going NPD. 
b)
 Hence refined as an inversion twin 
 
2.5. Antibacterial testing 
2.5.1 Bacterial strains and culture conditions 
The bacterial strains investigated include Bacillus subtilis DSM10, 
Enterobacter aerogenes DSM30053, Escherichia coli DSM1103, Escherichia coli 
DSM498, Pseudomonas fluorescens DSM50090, Pseudomonas putida DSM6125 
(KT2440) and Staphylococcus aureus DSM799 obtained from The Leibniz Institute 
DSMZ - German Collection of Microorganisms and Cell Cultures GmbH and the in-
house strains Escherichia coli T37-1 and Pseudomonas putida CP1. The organisms 
were maintained on nutrient agar at 4
0
C. Three of the bacteria are pathogenic or 
biohazard class II bacterial species; Enterobacter aerogenes DSM30053, Escherichia 
coli DSM1103 and Staphylococcus aureus DSM799. 
 
 
 
 
2.5.2 Determination of LC50   
Stock solutions of investigated compounds were freshly prepared and diluted 
with Mueller-Hinton broth to various working concentrations with a final DMSO 
concentration of ≤ 1%. 
LC50 values for the compounds were determined using a modification of the 
broth microdilution method described by Amsterdam.[26] Strains were grown in 
nutrient broth overnight, washed with phosphate buffered saline (PBS) and the cell 
number adjusted to give an optical density reading of 0.07 or 0.09, dependent on the 
bacterial strain, at 660 nm. Each well was inoculated with 5 μL of bacterial culture. 
Qualitative agar incorporation tests indicated that the LC50 of [BiCl2(-Sha-
1H)]∞ and BSS would be found in the 0-10 g/mL range against all bacteria and that 
Ampicillin had varying activities across the 0-500 g/mL range against all bacteria. In 
turn the LC50 of [BiCl2(-Sha-1H)]∞ and BSS were investigated using two fold 
dilutions in the 0.3125 -10 g/mL range and Ampicillin was tested using two fold 
dilutions ranging from 0.977 - 500µg/mL. Wells containing only the stock solutions 
of investigated compounds in Mueller-Hinton broth were used as blanks and wells 
containing only 1% DMSO in Mueller-Hinton broth and culture were used as positive 
controls. 
The microplates were incubated overnight at 30 °C for all bacteria except 
Enterobacter aerogenes DSM30053, Escherichia coli DSM1103 and Staphylococcus 
aureus DSM799 which were incubated at 37
o
C. The presence or absence of growth 
was determined by measuring the optical density of the wells at a wavelength of 
660 nm using a plate reader. The LC50 values were determined as the concentration or 
range of concentrations that caused a 50 % reduction in cell growth. 
 
3. Results and discussion 
3.1. Synthesis and characterisation of polymeric Bi chlorido hydroxamato complexes 
 BiCl3 was reacted with a slight excess of hydroxamaic acids (Sha, 2-NH2-
pha and 2-pyha) in anhydrous THF and stirred at stirred at RT for 72 hours. Solids 
were collected in reasonably good yields by filtration post stirring or post addition 
of H2O and their structures characterised by elemental analysis IR, 
1
H NMR 
spectroscopy and mass spectrometry and in the case of [BiCl2(-Sha-
1H)(THF)].THF∞ by X-ray crystallography.   
 
3.1.1 [BiCl2(-Sha-1H)]∞ 
  Elemental analyses indicates the formation of a 1:2:1 Bi(III) chlorido 
hydroxamic acid complex. The salicylhydroxamic acid ligand is therefore 
monodeprotonated. 
IR spectroscopy is a particularly useful technique for characterisation of 
metal hydroxamato complexes. A shift of the intense carbonyl stretching band in 
the free ligand, Sha (1619 cm
-1
), to lower wavenumber in the corresponding 
complex (1604 cm
-1
) was observed. This observation confirms the involvement of 
the carbonyl O in coordination of the metal ion and is consistent with previous 
reports, where hydroxamato coordination is (O,O’)-bidentate chelating, with 
coordination through the carbonyl oxygen atom and the deprotonated hydroxamic 
acid hydroxy group to form five-membered chelates.[22, 27] We have also 
previously observed similar shifts in Bi hydroxamato complexes which feature 
(O,O’)-bidentate chelating and (O,μ-O’)-bidentate bridging coordination 
modes.[11] 
 
1
H NMR spectra were carried out in methanol-d4 given all ligands and Bi 
complexes were readily soluble in methanol. No signals associated with the 
hydroxamic acid protons (N-H and O-H) or the 2-OH proton were observed as 
expected. Nonetheless characteristic shifts in aromatic protons in the ligands 
compared to the corresponding Bi complexes were observed. For instance we 
observe a significant shift in the doublet associated with the proton at the 6 
position (H
6
) on the aromatic ring, which is closest to the carbonyl group, from 
7.63 in the free Sha ligand to 7.90 ppm in [BiCl2(-Sha-1H)].  The remaining two 
signals associated with free Sha at 7.34 and 6.9 ppm were found at 7.34 and 6.9 
ppm respectively in [BiCl2(-Sha-1H)].  
The absence of a shift in the signal associated with the proton at the 3-
position on the aromatic ring (H
3
) which is found within a multiplet at 6.9 ppm, 
the elemental analysis indicating that salicylhydroxamic acid is monodeprotonated 
and the typical (C=O) shift associated with (O,O) chelating mode in the IR 
spectrum, strongly suggests the hydroxyl group at the 2-position does not 
coordinate to the Bi(III) centre.  
ESI-MS in the positive mode was used to identify the product fragments 
BiCl(Sha-1H) and Bi(Sha-1H)2 with mass peaks at 396.1 and 512.9 a.m.u respectively.  
The proposed polymeric structure for [BiCl2(-Sha-1H)]∞ is shown in Figure 6 
and is supported by the X-ray crystal structure of the THF-solvated [BiCl2(-Sha-
1H)(THF)].THF∞ described below. 
 
 
3.1.2. X-ray structural characterisation of [BiCl2(-Sha-1H)(THF)].THF∞ 
Single crystals of THF-solvated [BiCl2(-Sha-1H)(THF)].THF∞ were formed 
upon standing of the filtrate in 2.3.1. - synthesis of [BiCl2(-Sha-1H)]∞. 
The atomic numbering scheme and atom connectivity for [BiCl2(-Sha-
1H)(THF)].THF∞ are shown in Figures 4 and 5 and a selection of bond lengths and 
angles reported in Table 2. The structure of [BiCl2(-Sha-1H)(THF)].THF∞ consists of 
a charge neutral Bi(III) polymer where each Bi(III) centre has a coordination of 7 and 
possesses distorted pentagonal bipyramidal geometry. Each Bi(III) centre is 
coordinated to three chlorido ligands two of which are bridging with different but 
adjacent Bi(III) centres and a salicylhydroxamato ligand with an (O,μ-O’) chelating 
mode, where the deprotonated hydroxyl oxygen bridges with one adjacent Bi(III) 
centre. It is noteworthy that the oxygen bridge is asymmetric, where the bridging 
oxygen is significantly closer in length to the hydroxamato chelated Bi(III) centre (c. 
2.25 Å) as compared to the adjacent Bi(III) centre (c. 2.8 Å; see Table 2). We 
previously reported a Bi(III) nitrato salicylhydroxamato complex, [Bi6(CH3OH)2(
1
-
NO3)2(
2
-NO3)(OH2)2(Sha-1H)12](NO3)2, where the bismuth atoms are bridged by 
salicylhydroxamato ligands to form terminal Bi2-µ-O3 (Bi-O range = 2.226-
2.82Å).[11]  
The coordination sphere around each Bi(III) is completed by a coordinated 
THF molecule and each hydroxyl group at the 2-position on the aromatic ring of Sha 
forms a hydrogen bond to one uncoordinated THF molecule in the lattice. 
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Figure 4. ORTEP diagram of [BiCl2(-Sha-1H)(THF)].THF∞, featuring 
neighbouring environment of one Bi centre with adjacent Bi atoms continuing 
the chain; thermal ellipsoids are drawn on the 50% probability level; symmetry 
operation: 
I
 -0.5+x, 0.5-y, z.  
a
b
c
 
 
Figure 5.  ORTEP diagram of [BiCl2(-Sha-1H)(THF)].THF∞, featuring repeating 
units of the chain. 
 
 
 
Table 2. Selected bond lengths (Å) and angles (°) for [BiCl2(-Sha-
1H)(THF)].THF∞. 
 Lengths  Angles  Angles 
Bi(1)–O(2)  2.237(4) O(2)–Bi(1)–O(1) 70.88(14) O(1)–Bi(1)–O(5)#1 138.31(13) 
Bi(1)–O(1)  2.290(4) O(2)–Bi(1)–Cl(1) 92.25(11) Cl(1)–Bi(1)–O(5)#1 94.21(9) 
Bi(1)–Cl(1)  2.5190(17) O(1)–Bi(1)–Cl(1) 87.62(13) O(19)–Bi(1)–O(5)#1 99.76(13) 
Bi(1)–O(19)  2.641(5) O(2)–Bi(1)–O(19) 77.15(14) Cl(2)–Bi(1)–O(5)#1 75.99(9) 
Bi(1)–Cl(2)  2.7272(14) O(1)–Bi(1)–O(19) 79.86(17) O(2)–Bi(1)–Cl(4)#1 144.89(10) 
Bi(1)–O(5)#1  2.797(4) Cl(1)–Bi(1)–O(19) 165.68(11) O(1)–Bi(1)–Cl(4)#1 75.49(10) 
Bi(1)–Cl(4)#1  3.0159(15) O(2)–Bi(1)–Cl(2) 74.64(10) Cl(1)–Bi(1)–Cl(4)#1 96.19(5) 
Cl(2)–Bi(2)  3.0059(15) O(1)–Bi(1)–Cl(2) 145.51(10) O(19)–Bi(1)–Cl(4)#1 87.44(12) 
O(2)–Bi(2)  2.750(4) Cl(1)–Bi(1)–Cl(2) 94.01(5) Cl(2)–Bi(1)–Cl(4)#1 138.18(4) 
Bi(2)–O(5)  2.225(4) O(19)–Bi(1)–Cl(2) 92.43(13) O(5)#1–Bi(1)–
Cl(4)#1 
62.90(9) 
Bi(2)–O(4)  2.277(4) O(2)–Bi(1)–O(5)#1 150.28(13) Bi(1)–Cl(2)–Bi(2) 98.78(4) 
Bi(2)–Cl(3)  2.5255(16)     
Bi(2)–O(20)  2.709(5)     
Bi(2)–Cl(4)  2.7356(14)     
Cl(4)–Bi(1)#2  3.0160(15)     
Symmetry transformations used to generate equivalent atoms:  
#1 x–1/2,–y+1/2,z    #2 x+1/2,–y+1/2,z    #3 x+1,y,z 
 
3.1.3 [BiCl3(--Pha-1H)] 
  Elemental analyses indicates the formation of a 1:3:1 Bi(III) chlorido 
hydroxamic acid complex. The 2-aminophenylhydroxamic acid ligand is therefore 
charge neutral. 
In the IR spectrum a shift of the intense carbonyl stretching band in the free 
ligand, 2-NH2-pha (1639 cm
-1
), to lower wavenumber in the corresponding 
complex was observed (1614 cm
-1
). This observation again confirms hydroxamato 
coordination through the carbonyl oxygen atom and the deprotonated hydroxy 
group, (O,O’).[11, 22, 27] 
 Regarding the 
1
H NMR data in methanol-d4 for [BiCl3(--Pha-1H)] we 
observe significant shifts in all four of the aromatic signals found at 7.30, 7.16, 
6.74 (doublet, 1 H
3
) and 6.58 (triplet, H
4
) ppm for the free ligand to three signals 
at 7.70, 7.6 and 7.38 (multiplet, H
3&4
) ppm in the Bi(III) complex. Though the 
signal for the 2-amino protons are found at 4.59 ppm in the --Pha, no amino 
proton signals are observed in the Bi(III) complex.  
Given the dramatic shift in the signal associated with aromatic H found at 
the 6-position together with the loss or broadening of the amino signals it is likely 
that the amino group is either coordinated to Bi(III) or protonated.  
Significantly though given the elemental analysis indicates that 2-
aminophenylhydroxamic acid is charge neutral in the corresponding Bi(III) 
complex and the typical (C=O) shift associated with (O,O) chelating mode is 
observed in its IR spectrum, it is likely that the amino group at the 2-position is 
protonated while the hydroxamic acid functional group is monodeprotonated, -
-Pha-1H. We have solved the X-ray crystal structure of a separate Group V -
-Pha-1H compound, which features the suggested (O,O’) hydroxamato 
coordination mode and protonated amino group at the 2-position.{Griffith,  #480} 
ESI-MS in the positive mode was used to identify the product fragments 
BiCl2(2-NH3-pha-1H) and BiCl3(2-NH3-pha-1H)2 with mass peaks at 430.9 and 619 
a.m.u respectively.  
The proposed polymeric structure for [BiCl3(--Pha-1H)]∞ is shown in 
Figure 6 and is also supported by the X-ray crystal structure of the tetrahydrofuran 
(THF)-solvated [BiCl2(-Sha-1H)(THF)].THF∞. 
 
 
 Figure 6. Structure of [BiCl2(-Sha-1H)(THF)]∞ (a) and proposed structures of 
[BiCl2(-Sha-1H)]∞ (b) and [BiCl3(--Pha-1H)] (c). 
 
3.2. Antibacterial Activity of [BiCl2(-Sha-1H)]∞, Bismuth Subsalicylate and 
Ampicillin 
The antibacterial activity of [BiCl2(-Sha-1H)]∞ and the commercially available 
drug bismuth subsalicylate (BSS) were investigated in six environmental bacterial 
strains; E. coli DSM498, E. coli T37-1, P. putida DSM6125 (KT2440), P. putida CP1, 
P. fluorescens DSM50090 and  B. subtilis DSM10 and three biohazard class II 
pathogenic strains; E. coli DSM1103,  E. aerogenes DSM30053 and S. aureus 
DSM799. Ampicillin, a beta lactam broad spectrum antibiotic, which is on the WHO’s 
List of Essential Medicines, was chosen as a control compound. LC50 values, where 
LC50 is lethal concentration which inhibits the growth of 50% of viable cells present, 
were determined using the broth microdilution method, Table 3.[26]  
 
 
 
 
 
Table 3 – LC50 values (µg/mL) for [BiCl2(-Sha-1H)], BSS and Ampicillin against 
nine bacterial strains (± values = standard deviation).  
 
 
 
 
 
 
 
 
 
 
 
 
The bismuth compounds [BiCl2(µ-Sha-1H)] and BSS, exhibit similar 
antibacterial activity against all of the strains tested, although [BiCl2(µ-Sha-1H)] is 
slightly more active against every strains apart from P. putida DSM 6125.  The 
bismuth compounds do not display preferential activity for the Gram-positive (S. 
aureus and B. subtilis) over the Gram-negative bacteria or vice versa. 
In contrast Ampicillin exhibits diverse activity against the panel of bacteria. 
This antibiotic exhibits significantly superior activity (≤ 0.98 g/ mL) against all three 
strains of E. coli including the pathogenic strain, E. coli DSM 1103, as compared to 
the bismuth compounds (3.5-8.7 g/mL). It is noteworthy though that both bismuth 
compounds exhibit similar activity to Ampicillin against the remaining two 
pathogenic strains E. aerogenes DSM 30053 and S. aureus DSM 799. 
Bacteria Ampicillin [BiCl2(-Sha-1H)] BSS 
E. coli DSM 498 ≤ 0.98 5.7 ± 0.04 8.7 ± 0.032 
E. coli T37-1 ≤ 0.98 3.5 ± 0.036 7.4 ± 0.018 
E. coli DSM 1103* ≤ 0.98 6 ± 0.026 6.7 ± 0.01 
E. aerogenes DSM 30053* 7 ± 0.016 6.9 ± 0.024 7 ± 0.01 
P. putida DSM 6125 62.5 ± 0.02 4.7 ± 0.039 4.1 ± 0.09 
P. putida CP1 98 ± 0.019 3.9 ± 0.022 6 ± 0.05 
P. fluorescens DSM50090 > 500 2.3 ± 0.029 4.4 ± 0.03 
S. aureus DSM 799* 7.81 ±  0.012 5.8 ± 0.03 6.8 ± 0.028 
B. subtilis DSM 10 > 500 2.5 ± 0.032 4.6 ± 0.03 
The bismuth compounds have superior activity with respect to Ampicillin in 
four out of the six environmental strains, two of which are resistant to Ampicillin (P. 
fluorescens DSM50090 and B. subtilis DSM 10) with LC50 ≥ 500 g/mL. 
 
4. Conclusion 
The polymeric bismuth(III) chlorido  hydroxamato complexes [BiCl2(µ-Sha-
1H)] and [BiCl3(--Pha-1H)] were successfully synthesised and fully characterised.  
The structure of the THF solvated [BiCl2(-Sha-1H)(THF)].THF∞ was solved by X-ray 
crystallography, featuring the (O,μ-O’) chelating mode of the salicylhydroxamato 
ligand where the deprotonated hydroxyl oxygen bridges with one adjacent Bi(III) 
centre. There is no evidence to suggest that the secondary groups associated with Sha, 
and 2-apha, i.e. the hydroxyl group and amino group at the 2-position respectively, act 
as anchors and encourage coordination. 
An investigation of the antibacterial activity of [BiCl2(µ-Sha-1H)], BSS, and 
ampicillin against nine bacterial strains revealed that both bismuth compounds 
exhibited broad antibacterial activity in the experiments described including 
noteworthy activity against two pathogenic strains, E. aerogenes DSM 30053 and S. 
aureus DSM 799. Furthermore both bismuth compounds exhibited appreciable 
activity against six environmental bacterial strains and in four cases far superior 
activity than Ampicillin. This preliminary antibacterial study suggest that bismuth 
compounds should be investigated alone or in combination with antibiotics against 
multidrug resistant strains of antibiotics and could with further enquiry have a role to 
play in water disinfection.  
 
 
5. Supplementary material  
Crystallographic data (excluding structure factors) reported in this paper have been 
deposited with the Cambridge Crystallographic Data Centre, CCDC No. 832349. 
Copies of this information may be obtained free of charge from The Director, CCDC, 
12 Union Road, Cambridge CB2 1EZ, UK (fax: ++44-1223-336-033; e-mail: 
deposit@ccdc.cam.ac.uk or www: http://www.ccdc.cam.ac.uk/products/csd/request/). 
Atomic coordinates and equivalent isotropic displacement parameters, bond lengths 
and angles, anisotropic displacement parameters,  hydrogen coordinates and isotropic  
displacement parameters, torsion angles and hydrogen bonds  for [BiCl2(-Sha-
1H)(THF)].THF∞ are provided. 
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